Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Jindrich H. Kopecek

Theratarget, Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

TheraTarget, Inc.

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Professor Kopeček is a a tenured professor at the University of Utah who is interested in developing therapies for various diseases while also educating young, talented minds to follow in his passion and interests. The consortium agreement with the University of Utah involves Professor Kopeček's research laboratory. However, after careful review of Dr. Kopeček's interest with TheraTarget and the STTR project, the University of Utah's Conflict of Interest Office has determined, again with their annual review, that "no conflict of interest management plan is necessary".

Listed Research Project
Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

This Phase II proposal extends a successful Phase I project and further details the rationale and the research plan for the synthesis and characterization of backbone degradable, long-circulating polymer conjugates with anticancer drugs, gemcitabine and paclitaxel. The combination of two polymer-drug conjugates with diverse mechanisms of action will result in enhanced efficacy of ovarian cancer treatment and minimal adverse effects.

Filed on June 06, 2016.

Tell us what you know about Jindrich H. Kopecek's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Jindrich Kopecek University of Utah Conflict of Interest University of Utah Value cannot be readily determined
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page